Patents by Inventor Giancarlo Trani

Giancarlo Trani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240092773
    Abstract: The present invention relates to dihydro-cyclopenta-isoquinoline derivatives of formula (I): processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular, disorders caused by the interaction of IgE with the Fc?RI receptor.
    Type: Application
    Filed: December 22, 2020
    Publication date: March 21, 2024
    Inventors: Timothy John NORMAN, Zhaoning ZHU, Selvaratnam SUGANTHAN, Konstantinos RAMPALAKO, James MADDEN, Jag Paul HEER, Richard Jeremy FRANKLIN, Rickki Lee CONNELLY, Thierry DEMAUDE, Gregory William HASLETT, Benedicte LALLEMAND, Nathaniel Julius Thomas MONCK, Julian Hugh ROWLEY, Giancarlo TRANI
  • Publication number: 20230303517
    Abstract: The present invention relates to dihydrocyclopenta-isoquinoline-sulfonamide derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the Fc?RI receptor.
    Type: Application
    Filed: December 22, 2020
    Publication date: September 28, 2023
    Inventors: Timothy John NORMAN, Douglas BYRNE, Julian Hugh ROWLEY, Giancarlo TRANI, Konstantinos RAMPALAKOS, Nathaniel Julius Thomas MONCK, Benedicte LALLEMAND, Gregory William HASLETT, Rickki Lee CONNELLY, Jag Paul HEER, James MADDEN, Oliver PHILPS, Selvaratnam SUGANTHAN, Zeshan YOUSUF, Richard John MEARS
  • Publication number: 20230271951
    Abstract: A series of substituted 4,4-difluorocyclohexyl derivatives as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Application
    Filed: April 6, 2021
    Publication date: August 31, 2023
    Inventors: Prafulkumar Tulshibhai CHOVATIA, Anne Marie FOLEY, Gregory William HASLETT, Martin Clive HUTCHINGS, James Andrew JOHNSON, Fabien Claude LECOMTE, Nathaniel Julius Thomas MONCK, Joanna Rachel QUINCEY, Konstantinos RAMPALAKOS, James Thomas REUBERSON, Adam Peter SMALLEY, Giancarlo TRANI, Darshan Gunvant VAIDYA
  • Publication number: 20230051300
    Abstract: The present invention relates to tetrahydrobenzo-isoquinoline sulfonamides derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FIERI receptor.
    Type: Application
    Filed: December 22, 2020
    Publication date: February 16, 2023
    Inventors: Timothy John NORMAN, Oliver PHILPS, Gregory William HASLETT, Jag Paul HEER, Giancarlo TRANI
  • Publication number: 20220332709
    Abstract: Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.
    Type: Application
    Filed: June 20, 2019
    Publication date: October 20, 2022
    Inventors: Pfrafulkumar Tulshibhai Chovatia, Rickki Lee Connelly, Richard Jeremy Franklin, Gregory William Haslett, Alistair James Henry, James Madden, Judi Charlotte Neuss, Timothy John Norman, Oliver Philps, William Ross Pitt, Konstantinos Rampalakos, Matthew Duncan Selby, Suganthan Selvaratnam, Giancarlo Trani, Zhaoning Zhu
  • Patent number: 10287299
    Abstract: A series of substituted 3,4-dihydro-2H-.1,4-benzoxazin-3-one derivatives, and analogs thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neuradegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: May 14, 2019
    Assignee: UCB Biopharma SPRL
    Inventors: Gareth Neil Brace, Prafulkumar Tulshibhai Chovatia, Gregory Foulkes, James Andrew Johnson, Severine Danielle Jones, Boris Kroeplien, Fabien Claude Lecomte, Pui Leng Loke, Martin Alexander Lowe, Ajay Mandal, Timothy John Norman, Christopher Francis Palmer, Yolanda Pérez-Fuertes, John Robert Porter, Donald Smyth, Giancarlo Trani, Muhammed Uddin, Zhaoning Zhu
  • Publication number: 20180134728
    Abstract: A series of substituted 3,4-di-hydro-2H-.1,4-benzoxazin-3-one derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: June 7, 2016
    Publication date: May 17, 2018
    Inventors: Gareth Neil Brace, Prafulkumar Tulshibhai Chovatia, Gregory Foulkes, James Andrew Johnson, Severine Danielle Jones, Boris Kroeplien, Fabien Claude Lecomte, Pui Leng Loke, Martin Alexander Lowe, Ajay Mandal, Timothy John Norman, Christopher Francis Palmer, Yolanda Pérez-Fuertes, John Robert Porter, Donald Smyth, Giancarlo Trani, Muhammed Uddin, Zhaoning Zhu
  • Patent number: 8513248
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein A is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy, C1-3alkoxy C1-4alkyl, C1-2fluoroalkyl, halogen, NR6R7, optionally substituted heteroaryl (Het), or optionally substituted phenyl, and R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis or osteoarthritis or neurodegenerative disorders.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: August 20, 2013
    Assignee: Glaxo Group Limited
    Inventors: David Kenneth Dean, Jorge Munoz-Muriedas, Mairi Sime, Jon Graham Anthony Steadman, Rachel Elizabeth Anne Thewlis, Giancarlo Trani, Ian David Wall, Daryl Simon Walter
  • Patent number: 8501946
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein A is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy, C1-3alkoxy C1-4alkyl, C1-2fluoroalkyl, halogen, NR6R7, optionally substituted heteroaryl (Het), or optionally substituted phenyl, and R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis, osteoarthritis or neurodegenerative disorders.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: August 6, 2013
    Assignee: Glaxo Group Limited
    Inventors: David Kenneth Dean, Jorge Munoz-Muriedas, Mairi Sime, Jon Graham Anthony Steadman, Rachel Elizabeth Anne Thewlis, Giancarlo Trani, Daryl Simon Walter
  • Publication number: 20120172366
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein A is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy, C1-3alkoxy C1-4alkyl, C1-2fluoroalkyl, halogen, NR6R7, optionally substituted heteroaryl, or optionally substituted phenyl, and R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis or osteoarthritis or neurodegenerative disorders.
    Type: Application
    Filed: April 28, 2010
    Publication date: July 5, 2012
    Inventors: David Kenneth Dean, Jorge Munoz-Muriedas, Mairi Sime, Jon Graham Anthony Steadman, Rachel Elizabeth Anne Thewlis, Giancarlo Trani, Ian David Wall, Daryl Simon Walter
  • Publication number: 20120157436
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein A is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy, C1-3alkoxy C1-4alkyl, C1-2-fluoroalkyl, halogen, NR6R7, optionally substituted heteroaryl, or optionally substituted phenyl, and R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis, osteoarthritis or neurodegenerative disorders.
    Type: Application
    Filed: April 28, 2010
    Publication date: June 21, 2012
    Inventors: David Kenneth Dean, Jorge Munoz-Muriedas, Mairi Sime, Jon Graham Anthony Steadman, Rachel Elizabeth Anne Thewlis, Giancarlo Trani, Daryl Simon Walter
  • Patent number: 7960563
    Abstract: The present invention relates to novel indazole derivatives having pharmacological activity, processes for their preparation, compositions containing them and uses of these compounds in the treatment of estrogen receptor beta mediated diseases.
    Type: Grant
    Filed: March 5, 2008
    Date of Patent: June 14, 2011
    Assignee: Glaxo Group Limited
    Inventors: Christopher Norbert Johnson, David G Jones, Xi Liang, David Timothy MacPherson, Aaron B Miller, Antoinette Naylor, Steven James Stanway, Andrew Kenneth Takle, Giancarlo Trani
  • Patent number: 7956083
    Abstract: The present invention relates to novel indole derivatives having pharmacological activity, processes for their preparation, compositions containing them and the use of these compounds in the treatment of estrogen receptor beta mediated diseases.
    Type: Grant
    Filed: February 17, 2009
    Date of Patent: June 7, 2011
    Assignee: Glaxo Group Limited
    Inventors: Christopher Norbert Johnson, David G. Jones, Xi Liang, David Timothy MacPherson, Aaron B Miller, Steven James Stanway, Andrew Kenneth Takle, Giancarlo Trani, Antoinette Wilson
  • Publication number: 20100324106
    Abstract: The present invention relates to novel indole derivatives having pharmacological activity, processes for their preparation, compositions containing them and the use of these compounds in the treatment of estrogen receptor beta mediated diseases.
    Type: Application
    Filed: February 17, 2009
    Publication date: December 23, 2010
    Inventors: Christopher Norbert Johnson, David G. Jones, Xi Liang, David Timothy Macpherson, Aaron B. Miller, Steven James Stanway, Andrew Kenneth Takle, Giancarlo Trani, Antoinette Wilson
  • Publication number: 20100087502
    Abstract: The present invention relates to novel indazole derivatives having pharmacological activity, processes for their preparation, compositions containing them and uses of these compounds in the treatment of estrogen receptor beta mediated diseases.
    Type: Application
    Filed: March 5, 2008
    Publication date: April 8, 2010
    Applicant: GLAXO GROUP LIMITED
    Inventors: Christopher Norbert Johnson, David G. Jones, Xi Liang, David Timothy Macpherson, Aaron B. Miller, Antoinette Naylor, Steven James Stanway, Andrew Kenneth Takle, Giancarlo Trani
  • Publication number: 20080058391
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein; each of R1 to R4 is independently selected from hydrogen and C1-4 alkyl and each of rings A and B independently is optionally further substituted by up to three substituents, each of which is independently selected from the group consisting of halogen, hydroxy, C1-4alkoxy, C1-4alkyl, C1-5alkanoyl, CF3, CF3O and cyano; with the proviso that ring A must contain at least one CF3 group, are useful in the treatment of diseases and conditions mediated by modulation of use-dependent voltage-gated sodium channels.
    Type: Application
    Filed: August 8, 2007
    Publication date: March 6, 2008
    Applicant: GLAXO GROUP LIMITED
    Inventors: Christopher Johnson, David MacPherson, Giancarlo Trani
  • Publication number: 20070191345
    Abstract: The present invention relates to novel quinoline derivatives such as compounds of the formula (I): and the use of such compounds or pharmaceutical compositions thereof in the treatment of CNS and other disorders.
    Type: Application
    Filed: March 24, 2005
    Publication date: August 16, 2007
    Applicant: GLAXO GROUP LIMITED
    Inventors: Mahmood Ahmed, Christopher Johnson, Neil Miller, Giancarlo Trani, David Witty